A prospective, multicenter, noninterventional study in Taiwan to evaluate the safety and tolerability of lacosamide as adjunctive therapy for epilepsy in clinical practice
Journal
Epilepsy and Behavior
Journal Volume
113
Pages
107464
Date Issued
2020
Author(s)
Wu T.
Chuang Y.-C.
Huang H.-C.
Lim S.-N.
Hsieh P.F.
Cheng M.-Y.
Tsai M.-H.
Jou S.-B.
Chang C.-W.
Hsieh H.-Y.
Du X.
Hellot S.
McClung C.
Hung C.
Abstract
Rationale: Lacosamide (LCM) was initially approved in Taiwan in March 2014 for use as adjunctive therapy for focal impaired awareness seizures and secondarily generalized seizures (SGS) in patients with epilepsy ? 16 years of age. The efficacy and tolerability of adjunctive LCM for the treatment of patients with focal seizures have been demonstrated in randomized, placebo-controlled trials. However, the trials do not reflect a flexible dose setting. This study (EP0063) was conducted to assess the safety and tolerability of LCM in real-world clinical practice in Taiwan. Effectiveness of LCM was also assessed as an exploratory objective. Methods: EP0063 was a multicenter, prospective, noninterventional study with an expected observation period of 12 months ± 60 days. Eligible patients were ? 16 years of age, had focal impaired awareness seizures and/or SGS (in line with approved indication in Taiwan at the time of the study), were taking at least one concomitant antiseizure medication (ASM), and had at least one seizure in the 3 months before baseline. Patients were prescribed LCM by their treating physician in the course of routine clinical practice. The primary safety variable was treatment-emergent adverse events (TEAEs) spontaneously reported to, or observed by, the treating physician. Based on safety data from previous studies of LCM and known side effects of other ASMs, certain TEAEs (including but not limited to cardiac and electrocardiogram, suicidality, and rash related terms) were analyzed separately. Effectiveness variables included Clinical Global Impression of Change (CGIC) and change in 28-day seizure frequency from baseline to 12 months (or final visit), and freedom from focal seizures. Results: A total of 171 patients were treated with LCM, of whom 139 (81.3%) completed the study. The Kaplan–Meier estimated 12-month retention was 82.9%. Patients had a mean (standard deviation [SD], range) age of 38.5 (14.0, 16–77) years, and 96 (56.1%) were male. Patients were taking a mean (SD, range) of 2.8 (1.1, 1–6) ASMs at baseline. Mean (SD, range) duration of LCM treatment was 288.7 (111.9, 2–414) days, and the mean (SD, range) daily dosage of LCM was 205.0 (82.7, 50.0–505.2) mg/day. Overall, 95 (55.6%) patients reported at least one TEAE, most commonly dizziness (33 [19.3%] patients). Drug-related TEAEs were reported in 74 (43.3%) patients, and drug-related TEAEs leading to discontinuation of LCM were reported in 14 (8.2%) patients. Two (1.2%) patients died during LCM treatment, which were considered not related to LCM. Two (1.2%) patients had suicidality-related TEAEs; these TEAEs were considered either not related to LCM or the relationship was not recorded. Rash-related TEAEs were reported in five (2.9%) patients (considered LCM-related in two patients). Based on the CGIC, at 12 months (or final visit), 109 (63.7%) patients were considered to have improved, 54 (31.6%) had no change, and the remaining eight (4.7%) were minimally worse. At 12 months (or final visit), the median percentage change in focal seizure frequency was –50.0. During the first 6 months of the study, 21 (12.3%) patients were free from focal seizures; 37 (21.6%) patients were free from focal seizures in the last 6 months of the study; and 14 (8.2%) were free from focal seizures for the full 12 months of the study. Conclusions: Results of this prospective, noninterventional study suggest that adjunctive LCM was generally safe and well tolerated in this patient group in real-world practice in Taiwan. Effectiveness was also favorable, with more than 60% of patients considered to be improved by their physician at 12 months (or final visit). ? 2020 The Authors
Subjects
Effectiveness; Epilepsy; Focal seizures; Lacosamide; Taiwan; Tolerability
SDGs
Other Subjects
lacosamide; acetamide derivative; anticonvulsive agent; lacosamide; adult; adverse event; age; Article; clinical practice; death; dizziness; drug efficacy; drug safety; drug screening; drug tolerability; drug withdrawal; electrocardiography; epilepsy; female; focal epilepsy; headache; heart disease; human; major clinical study; major depression; male; medication therapy management; multicenter study; observation; prospective study; psychosis; rash; seizure; somnolence; suicidal behavior; Taiwan; treatment duration; upper respiratory tract infection; aged; clinical trial; combination drug therapy; epilepsy; infant; middle aged; treatment outcome; Acetamides; Adult; Aged; Anticonvulsants; Drug Therapy, Combination; Epilepsy; Humans; Infant; Lacosamide; Male; Middle Aged; Prospective Studies; Taiwan; Treatment Outcome
Publisher
Academic Press Inc.
Type
journal article